A/Prof Miriam Levy

Associate Professor Miriam Levy

Gastroenterologist and Hepatologist

MBBS (Hons I) UNSW, FRACP, PhD USYD
Head of Department, Gastroenterology and Liver Service

  Research interests:
Hepatitis B virus infection and pregnancy and Chronic Liver Disease

  Clinical Expertise:
Liver Disease and Cancer, General Gastroenterology, Bowel Cancer Screening

Profile

A/Professor Miriam Levy is a staff specialist and Department Head at the Gastroenterology and Liver Department, Liverpool Hospital. A/Prof Levy completed her medical degree at the University of New South Wales in 1990 (Hons Class 1). In 1996, she was awarded the Fellowship of the Royal Australasian College of Physicians (FRACP), and received her gastroscopy and colonoscopy training recognition from the Gastroenterological Society of Australia (GESA) Conjoint Committee. Following this, she achieved a Doctor in Philosophy 2001 University of Sydney Dissertation: “Role of Fibroblast Activation Protein and other members of the oligopeptidase family in human cirrhosis”.

A/Prof Levy is actively involved in clinical research, including international and national sponsored and investigator led clinical trials. Her investigator led research has addressed clinical questions in viral hepatitis and liver disease and includes work presented in 45 peer reviewed publications, H index 15 and 1300 citations. Her focus in Hepatitis B and C and liver cancer reflects the significant morbidity and mortality from these conditions in her local community due to the extraordinarily high local prevalence. Her clinical expertise includes hepatitis B and C, multidisciplinary management of liver cancer, management of acute gastrointestinal emergencies and related hospitalisations, colon cancer surveillance, evaluation of gastrointestinal symptoms and management of chronic liver disease.

Education

MB BS (Hons class 1)
University of New South Wales 1990

FRACP
Fellowship of the Royal Australian College of Physicians 1996

Ph.D. in Medicine Dissertation
Thesis Title: “Role of Fibroblast Activation Protein and other members of the oligopeptidase family in human cirrhosis” University of Sydney 2001

Conjoint Committee Certified
in Endoscopy and colonoscopy 1996

Positions

Staff Specialist (2012 - current)
Head of Department of Gastroenterology and Liver
Liverpool Hospital

Staff Specialist (2002 – 2012)
Department of Gastroenterology and Liver
Liverpool Hospital
Conjoint Associate Professor (2014 – current)
University of Western Sydney

Conjoint Associate Professor (2014 - current)
University of New South Wales

Chair, Hepatitis Governance and Advisory Committee SSWLHD (2010-present)

NSW Representative
Australian Liver Association (ALA) Chapter of Gastroenterology Society of Australia (GESA)

Medical Staff Council Treasurer (prior chair)
Liverpool Hospital

Steering Committee Member
National Clinical Trials Network for Australian Liver Association

Select Publications

  1. Hepatitis C treatment for difficult to access populations; can telementoring (as distinct from telemedicine) help? Mohsen W, Chan P, Whelan M, Glass A, Mouton M, Yeung E, Trinh Q, Arora S, Davison S, Lama T, Cobrador C, Levy MT.
    Intern Med J. 2018 Aug 8. doi: 10.1111/imj.14072. PMID: 30091164
  2. Mother-to-child transmission of hepatitis B: Examining viral cut-offs, maternal HBsAg serology and infant testing. Thilakanathan C, Wark G, Maley M, Davison S, Lawler J, Lee A, Shackel N, Nguyen V, Jackson K, Glass A, Locarnini SA, Levy MT. Liver Int. 2018 Jul;38(7):1212-1219. doi: 10.1111/liv.13736. Epub 2018 Mar 31. PMID:29532580
  3. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. Roberts SK, Lim R, Strasser S, Nicoll A, Gazzola A, Mitchell J, Siow W, Khoo T, Hamarneh Z, Weltman M, Gow P, Janko N, Tse E, Mishra G, Cheng EH, Levy M, Cheng W, Sood S, Skoien R, Mitchell J, Zekry A, George J, MacQuillan G, Wigg A, Stuart K, Sievert W, McCaughan G; ALA Clinical Research Network. Clin Gastroenterol Hepatol. 2018 Feb;16(2):268-277. pii: S1542-3565(17)31238-7. doi: 10.1016/j.cgh.2017.09.063. PMID:29050991
  4. Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. Lubel J, Strasser S, Stuart KA, Dore G, Thompson A, Pianko S, Bollipo S, Mitchell JL, Fragomeli V, Jones T, Chivers S, Gow P, Iser D, Levy M, Tse E, Gazzola A, Cheng W, Nazareth S, Galhenage S, Wade A, Weltman M, Wigg A, MacQuillan G, Sasadeusz J, George J, Zekry A, Roberts SK; Australian Liver Association Clinical Research Network (ALA CRN). Antivir Ther. 2017 Apr 19. doi: 10.3851/IMP3168. PMID: 28422043
  5. Hepatitis A to E: what's new? Mohsen W, Levy MT. Intern Med J. 2017 Apr;47(4):380-389. doi: 10.1111/imj.13386. PMID: 28401719

For enquiries or appointments, call us between 9.30am – 12pm, Monday to Friday

Gastroenterology and Liver
Clinic E (123), Level 1
Liverpool Hospital
Corner of Elizabeth and Goulburn Streets
LIVERPOOL NSW 2170

  FAX: 02 8738 3094
  SWSLHD-LiverpoolGastro@health.nsw.gov.au

8.30am - 4.00pm
Monday to Friday

© 2014-2020 Department of Gastroenterology & Liver, Liverpool Hospital | Privacy Policy | Disclaimer | Website design: WebInjection